Akari Therapeutics PLC reports a Return on Equity (ROE) of -195.05%.

What is AKTX's dividend yield?

Akari Therapeutics PLC offers a dividend yield of 0.00%.

What is AKTX's Quality Score?

Our AI rates AKTX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy AKTX?

Our AI Timing Score for AKTX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does AKTX belong to?

Akari Therapeutics PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Akari Therapeutics PLC (AKTX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

AKTX AI Analysis Summary

Our AI summary for AKTX: Akari Therapeutics PLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -195.05%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

AKTX

Akari Therapeutics PLC

US:NASDAQ STOCK Healthcare >> Biotechnology News 61

USD 7.50

-0.29 (-3.72%) Day Change

Watchlist Portfolio Compare Chart

0.05

D/E

-195.1%

ROE

-82.8%

ROA

0.00%

Div Yield

AKARI THERAPEUTICS PLC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 7.50 Price -0.29 (-3.72%) Day Change	NEWS SCORE: 61

AKTX, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	61
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	7.50
PBV / Sector	0.95 / 44,105.10 GREAT
Earning Per Share	-15.43

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.39 M GREAT
Average 1W Daily Value	0.21 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	N/A / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-82.76 / 185,260.64
ROA Average (%) / Sector	-103.23 / 36,684.64
ROA Change Average (%) / Sector	29.39 / 422,221.42 GREAT
ROE (%) / Sector	-195.05 / 243,761.81
ROE Average (%) / Sector	606.84 / 48,758.38 GREAT
ROE Change Average (%) / Sector	-113.76 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:36
Symbol	AKTX
Name	AKARI THERAPEUTICS PLC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	1.75 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	13.64 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 401 East Jackson Street, Tampa, FL, United States, 33602

Phone: 929 274 7510

Website: https://www.akaritx.com

Sector: Healthcare >> Biotechnology

Description: Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.